ArticleInternational journal of molecular sciences2026
A Functional Evaluation of Resveratrol-Paclitaxel Combination Reveals Enhanced Apoptotic Responses in HeLa Cells.
Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study evaluated the combined effects of resveratrol (RES) and paclitaxel (PAC) on cell viability, apoptotic responses, and associated cellular processes in HeLa cervical cancer cells. Antiproliferative activity was assessed using XTT assay and combination index (CI) analysis, while apoptosis, cell cycle distribution, mitochondrial membrane potential (ΔΨm), and intracellular reactive oxygen species (ROS) levels were examined by flow cytometry-based approaches. The RES + PAC combination produced a synergistic reduction in cell viability compared to single treatments. This effect was accompanied by increased apoptotic cell populations and a marked accumulation of cells in the G2/M phase. Combined treatment was also associated with a pronounced loss of mitochondrial membrane potential and elevated ROS levels. Gene expression analysis indicated an increased
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.